Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.

In striking contrast to plasma VEGF levels, we found a highly significant reduction of VEGF levels in subcutaneous as well as intraabdominal wound fluid of patients who had received BV during neoadjuvant CTx (subcutaneous day 1: P =0.003, intraabdominal day 1: P =0.001).

also in 132,142 other papers